Citadel Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-80,900
| Closed | -$340K | – | 15797 |
|
|
2023
Q1 | $340K | Sell |
80,900
-4,300
| -5% | -$22.3K | ﹤0.01% | 9126 |
|
|
2022
Q4 | $512K | Buy |
85,200
+16,100
| +23% | +$87.9K | ﹤0.01% | 8187 |
|
|
2022
Q3 | $402K | Sell |
69,100
-3,400
| -5% | -$21.2K | ﹤0.01% | 8935 |
|
|
2022
Q2 | $433K | Buy |
72,500
+24,600
| +51% | +$126K | ﹤0.01% | 8969 |
|
|
2022
Q1 | $224K | Sell |
47,900
-8,500
| -15% | -$25.4K | ﹤0.01% | 11259 |
|
|
2021
Q4 | $140K | Buy |
56,400
+36,200
| +179% | +$88.6K | ﹤0.01% | 12364 |
|
|
2021
Q3 | $60K | Sell |
20,200
-11,000
| -35% | -$30K | ﹤0.01% | 13271 |
|
|
2021
Q2 | $78K | Buy |
31,200
+11,300
| +57% | +$27.1K | ﹤0.01% | 13095 |
|
|
2021
Q1 | $58K | Sell |
19,900
-56,800
| -74% | -$185K | ﹤0.01% | 12832 |
|
|
2020
Q4 | $247K | Buy |
76,700
+34,200
| +80% | +$114K | ﹤0.01% | 9422 |
|
|
2020
Q3 | $91K | Buy |
+42,500
| New | +$54.3K | ﹤0.01% | 9330 |
|
|
2019
Q2 | – | Sell |
-18,500
| Closed | -$18K | – | 10368 |
|
|
2019
Q1 | $18K | Buy |
18,500
+3,400
| +23% | +$3.58K | ﹤0.01% | 9085 |
|
|
2018
Q4 | $11K | Sell |
15,100
-9,800
| -39% | -$16.1K | ﹤0.01% | 8922 |
|
|
2018
Q3 | $54K | Buy |
24,900
+11,900
| +92% | +$29.5K | ﹤0.01% | 8793 |
|
|
2018
Q2 | $65K | Buy |
+13,000
| New | +$56.9K | ﹤0.01% | 8383 |
|
|
2018
Q1 | – | Sell |
-11,600
| Closed | -$31K | – | 9236 |
|
|
2017
Q4 | $31K | Buy |
+11,600
| New | +$34K | ﹤0.01% | 7765 |
|
|
2016
Q4 | – | Sell |
-1,260
| Closed | -$5K | – | 8373 |
|
|
2016
Q3 | $5K | Buy |
+1,260
| New | +$4.59K | ﹤0.01% | 7159 |
|
|
2016
Q2 | – | Sell |
-1,150
| Closed | -$6K | – | 7959 |
|
|
2016
Q1 | $6K | Buy |
1,150
+290
| +34% | +$2.32K | ﹤0.01% | 6623 |
|
|
2015
Q4 | $11K | Sell |
860
-120
| -12% | -$1.6K | ﹤0.01% | 8256 |
|
|
2015
Q3 | $14K | Sell |
980
-1,400
| -59% | -$24.2K | ﹤0.01% | 8369 |
|
|
2015
Q2 | $46K | Buy |
2,380
+1,460
| +159% | +$28.2K | ﹤0.01% | 7713 |
|
|
2015
Q1 | $17K | Sell |
920
-50
| -5% | -$1.13K | ﹤0.01% | 8026 |
|
|
2014
Q4 | $23K | Sell |
970
-540
| -36% | -$12.5K | ﹤0.01% | 7724 |
|
|
2014
Q3 | $37K | Buy |
1,510
+390
| +35% | +$10.1K | ﹤0.01% | 7104 |
|
|
2014
Q2 | $31K | Sell |
1,120
-2,680
| -71% | -$80.5K | ﹤0.01% | 7070 |
|
|
2014
Q1 | $129K | Buy |
3,800
+3,320
| +692% | +$113K | ﹤0.01% | 5944 |
|
|
2013
Q4 | $9K | Buy |
+480
| New | +$8.74K | ﹤0.01% | 6746 |
|
Other funds holding CTIC
Citadel Advisors's CTIC Position: Q2 2023 in Review
Citadel Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3,662 shares — an estimated $15.4K sold.
Citadel Advisors first reported a position in CTIC in Q3 2013 and held it in 25 quarters. The position peaked at $4.89M in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Citadel Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 3,662 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $15.4K.
- Citadel Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2013 and held it in 25 quarters.
- Citadel Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.89M in Q2 2022.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.